Silence Therapeutics PLC (SLN)
13.98
-1.30
(-8.54%)
USD |
NASDAQ |
Nov 14, 16:00
13.98
0.00 (0.00%)
After-Hours: 18:16
Silence Therapeutics Debt to Equity Ratio: 0.00 for June 30, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2024 | 0.00 |
| March 31, 2024 | 0.00 |
| December 31, 2023 | 0.00 |
| September 30, 2023 | 0.00 |
| June 30, 2023 | 0.00 |
| March 31, 2023 | 0.00 |
| December 31, 2022 | 0.00 |
| September 30, 2022 | 0.00 |
| Date | Value |
|---|---|
| June 30, 2022 | 0.00 |
| March 31, 2022 | 0.00 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | |
| December 31, 2020 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
Dec 2020
--
Maximum
Dec 2020
--
Average
--
Median
Dec 2020
Debt to Equity Ratio Benchmarks
| NuCana PLC | -- |
| TC BioPharm (Holdings) PLC | -- |
| Biodexa Pharmaceuticals PLC | -- |
| Adaptimmune Therapeutics PLC | 0.2592 |
| Verona Pharma PLC | 0.9197 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 238.59M |
| Total Liabilities (Quarterly) | 96.29M |
| Shareholders Equity (Quarterly) | 142.30M |
| Current Ratio | 9.830 |